Hematology
Blood & lymphatic clinical trials
Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We’re tracking 4,915 recruiting studies in this area right now.
By phase
- Not applicable2,022
- Phase 21,072
- Phase 1791
- Phase 1/Phase 2478
- Phase 3344
- Phase 4125
- Phase 2/Phase 383
Top conditions
- Multiple Myeloma327
- Acute Myeloid Leukemia280
- Lymphoma178
- Sickle Cell Disease133
- Myelodysplastic Syndromes128
- Acute Lymphoblastic Leukemia118
- Leukemia100
- Chronic Lymphocytic Leukemia95
- Follicular Lymphoma70
- Hematologic Malignancy67
- Myelodysplastic Syndrome64
- Hodgkin Lymphoma63
- Mantle Cell Lymphoma62
- Anemia56
- Diffuse Large B Cell Lymphoma54
- Malignant Solid Neoplasm53
- Acute Myeloid Leukemia (AML)48
- Lymphedema48
Leading sponsors
- M.D. Anderson Cancer Center145
- Institute of Hematology & Blood Diseases Hospital, China138
- National Cancer Institute (NCI)96
- The First Affiliated Hospital of Soochow University67
- Memorial Sloan Kettering Cancer Center63
- City of Hope Medical Center58
- Mayo Clinic55
- Assistance Publique - Hôpitaux de Paris45
- St. Jude Children's Research Hospital44
- Peking University People's Hospital43
Where studies are running
- California396
- Texas185
- Alabama156
- Maryland152
- Arizona125
- Florida105
- Massachusetts102
- New York98
- Ohio70
- Minnesota69
Recruiting studies4,915 total
- NCT07257835Recruiting
Dupilumab for tough stomach and gut diseases
This trial tests if dupilumab can help people with hard-to-treat stomach ulcers linked to eosinophilic gastrointestinal disorders (EGIDs), where a type of white blood cell builds up in the gut. It may offer a new option for those who haven't gotten better with other treatments.
ShanghaiAges 1–18 - NCT07255963RecruitingPhase 2
Pirtobrutinib, Lisaftoclax, and Rituximab for relapsed DLBCL
This trial tests a combination of three drugs—pirtobrutinib, lisaftoclax, and rituximab—for people with relapsed or refractory DLBCL who have already had at least one prior treatment. The goal is to see if this combination can help shrink or control the lymphoma.
Suzhou, JiangsuAges 18 years+ - NCT07257510Recruiting
Pomalidomide plus two other drugs for untreated Mantle Cell Lymphoma
This trial tests a combination of three drugs (pomalidomide, orelabrutinib, and zuberitamab) in people with Mantle Cell Lymphoma who have not yet received treatment. It aims to see if this combination works better than standard therapy, especially for those with high-risk features.
Beijing, Beijing MunicipalityAges 18–80 - NCT07252050RecruitingPhase 1/Phase 2
Ruxolitinib and half-matched transplant for severe sickle cell disease
This trial tests a new approach using the drug ruxolitinib to help a half-matched bone marrow transplant work better for people with severe sickle cell disease. It aims to reduce complications and improve outcomes.
Aurora, ColoradoAges 12–45 - NCT07257419RecruitingPhase 1
CAR T cells and stem cell transplant for leukemia and lymphoma
This trial tests giving special immune cells (CAR T cells) after a half-matched stem cell transplant. It's for children and young adults with high-risk leukemia or lymphoma that has come back or not responded to treatment.
Memphis, TennesseeAges Up to 21 years - NCT07253129Recruiting
Stem cell transplant study for T-cell lymphoma patients with partial response
This study compares two types of stem cell transplants (from a donor or your own cells) for people with certain T-cell lymphomas who had only a partial response to first chemotherapy. It aims to see which approach may work better.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT07257679RecruitingPhase 4
Gentle touch for arm swelling after breast cancer surgery
This study tests a gentle hand-on technique (called Gentle Touch) to see if it helps reduce arm swelling in women who developed lymphedema after breast cancer surgery. It may offer a new way to manage this side effect.
Roma, RMAges 30–75 - NCT07254312Recruiting
Venetoclax blood levels and side effects in AML
This trial checks how the amount of venetoclax in your blood relates to side effects after you are in remission from AML. It aims to help doctors find the safest dose for you.
Pavia, PaviaAges Any age - NCT07252336RecruitingPhase 2
CAR-T cell therapy for newly diagnosed Ph+ B-cell ALL
This trial tests a CAR-T cell therapy for adults who have just been diagnosed with a type of leukemia called Ph+ B-cell ALL. The treatment uses specially engineered immune cells to target and destroy cancer cells that have a specific marker (CD19 and CD22) and the Philadelphia chromosome. It may be an option for those who have not yet started standard chemotherapy.
Hangzhou, ZhejiangAges 18 years+ - NCT07257055RecruitingPhase 2
New drug combo for aggressive mantle cell lymphoma
This trial tests a two-step treatment for people with a fast-growing form of mantle cell lymphoma (MCL). First, you take a daily pill (BTKi) plus an infusion (rituximab), then a newer targeted therapy (glofitamab) to try to make the response last. The goal is to shrink the cancer and keep it away.
Houston, TexasAges 18 years+ - NCT07258680Enrolling by invitationPhase 3
Testing brentuximab and etoposide for T-cell lymphoma
This trial tests whether adding the drugs brentuximab and etoposide to standard chemotherapy improves treatment for people newly diagnosed with T-cell lymphoma. It aims to find a more effective first treatment option.
Ages 18–70 - NCT07255391Enrolling by invitationPhase 4
Platelet-rich plasma for healing deep skin ulcers
This trial tests whether a treatment made from your own blood (platelet-rich plasma) can help heal deep skin ulcers (Grade III) that have been present for more than two weeks. It may be a good option if you have a normal platelet count and are not in palliative care.
L'Ametlla del Vallès, BarcelonaAges 18 years+ - NCT07250217Recruiting
Study of AML epigenetic markers in older adults
This trial looks at certain chemical changes in blood cells of two groups of people aged 60 or older: those having heart surgery (control group) and those with a type of blood cancer called acute myeloid leukemia (AML) who will be treated with a drug called azacitidine. The goal is to find markers that could help personalize treatment for AML in seniors.
Mulhouse, AlsaceAges 60 years+ - NCT07259356Enrolling by invitation
Blood-flow-restriction training for hemophilia patients
This trial tests whether a special type of exercise that limits blood flow is safe and possible for people with hemophilia. It might help strengthen muscles without causing joint bleeds.
Bonn, North Rhine-WestphaliaAges 18 years+ - NCT07256158RecruitingPhase 3
Reducing radiation for early unfavorable Hodgkin lymphoma
This trial tests whether a lower dose of radiation, guided by PET scans, is safe and effective for people with early-stage but unfavorable Hodgkin lymphoma. It aims to reduce side effects while keeping the treatment strong.
AlessandriaAges 18 years+ - NCT06902012RecruitingPhase 1/Phase 2
Second infusion of CAR-T based on ctDNA for large B-cell lymphoma
This trial tests whether a second infusion of a CAR-T cell therapy called Axi-cel, given early based on a blood test (ctDNA), can help people with relapsed or hard-to-treat large B-cell lymphoma. If you had a partial response or your ctDNA stayed positive after the first dose, you may be eligible.
Guangzhou, GuangdongAges 18 years+ - NCT06560372Recruiting
Bleeding after head injury and brain blood vessel narrowing
This study looks at whether moderate to severe traumatic brain injury with bleeding around the brain can lead to a complication called cerebral vasospasm (narrowing of brain blood vessels). It's being done at Martinique University Hospital to understand how often this happens and how it affects recovery.
Fort-de-FranceAges 18 years+ - NCT06529874Recruiting
Pain, balance, and strength in children with sickle cell
This study looks at how children (ages 9-14) with sickle cell anemia or who are healthy handle pressure, balance, and strength. It aims to understand pain and movement better to help improve care.
GizaAges 9–14 - NCT07248176Recruiting
Universal CAR-T therapy for multiple myeloma
This trial tests a universal CAR-T cell therapy (made from donated cells) for multiple myeloma that has come back after at least two prior treatments. It may be an option if your cancer cells have a specific marker called BCMA and you have not had certain prior therapies.
ShanghaiAges 18 years+ - NCT07248163Recruiting
Universal CAR-T cell therapy for non-Hodgkin lymphoma
This trial tests a universal CAR-T cell therapy for patients with non-Hodgkin lymphoma whose cancer cells have CD19 on their surface. It might help if standard treatments have not worked.
ShanghaiAges 18 years+ - NCT07247188RecruitingPhase 3
Pneumococcal vaccine study for children with sickle cell disease
This trial tests a single dose of a new pneumococcal vaccine (21-valent) in children and teens with sickle cell disease. It aims to see if the vaccine can help protect against serious infections caused by pneumococcus bacteria, which are especially dangerous for people with SCD.
Atlanta, GeorgiaAges 2–17 - NCT07244406RecruitingPhase 2
CAR-T cell therapy for relapsed B-ALL
This trial is testing a new CAR-T cell therapy (Senl_B19) for children and young adults with B-cell acute lymphoblastic leukemia (B-ALL) that has returned or not responded to treatment. It targets a protein called CD19 on leukemia cells to help your immune system attack the cancer.
BeijingAges 3–25 - NCT06905106Recruiting
Polycythemia proteins and red blood cell study
This trial studies proteins and red blood cell production in people with polycythemia (high red blood cell count) to understand its causes. It may help improve care for patients with this condition.
DijonAges 18 years+ - NCT07249346RecruitingPhase 2
Preventing GVHD after stem cell transplant with three drugs
This trial tests a three-drug combination (cyclophosphamide, tacrolimus, and ruxolitinib) to prevent graft-versus-host disease (GVHD) after a stem cell transplant. It is for people with certain blood cancers who have a matched donor and can tolerate high-dose chemotherapy.
Birmingham, AlabamaAges 18 years+
Common questions
- How many blood & lymphatic clinical trials are recruiting?
- Clin2 is tracking 4,915 recruiting hematology studies from the U.S. registry right now, out of 7,288 we cover in this area in total.
- What does “Blood & lymphatic” cover here?
- Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We group each study into blood & lymphatic based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a blood & lymphatic trial near me?
- Use the search to filter blood & lymphatic studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.